The Bioactive Conformation of Neuropeptide Y Analogues at the Human Y2‐Receptor
Open Access
- 1 August 1997
- journal article
- Published by Wiley in European Journal of Biochemistry
- Vol. 247 (3) , 1019-1028
- https://doi.org/10.1111/j.1432-1033.1997.01019.x
Abstract
Several attempts to investigate the bioactive conformation of neuropeptide Y have been made so far. As cyclic peptides are much more rigid than linear ones, we decided to synthesise cyclic analogues of the C-terminal dodekapeptide amide neuropeptide Y Ac-25-36. Cyclisation was performed by side chain lactamisation of ornithine or lysine and glutamic or aspartic acid. The affinity of the 19 peptides ranged from K1 0.6 nM to greater than 10000 nM. We found that the size, position, orientation, configuration, and the location of the cycle plays an important role for receptor recognition. Circular dichroic studies have been performed to characterise the secondary structure of each peptide. Receptor binding studies were carried out on human neuroblastoma cell lines SK-N-MC (Y1) and SMS-KAN (Y2), and on rabbit kidney membranes (Y2). The pharmacological and spectral data showed that the α-helix content was not the predominant factor for high Y1-receptor affinity. Instead, the location and the size of the hydrophobic lactam bridge, and the conserved C-terminal tetrapeptide (Arg-Glu-Arg-Tyr) seemed to be the main parameters. Using molecular dynamics, the structures of four cyclic peptides (i,i+4) have been investigated and compared with the previously published NMR structure of one of the cyclic peptide analogues. Significant differences have been found in the overall three-dimensional fold of the peptides. The distances between the N- and the C-terminus allow discrimination between peptides with high binding affinity and those with low binding affinity, because of the correlation that was found with the measured affinity. Thus, this study suggests that a turn-like structure and the orientation of the C-terminus towards the N-terminus play major roles for high affinity binding of cyclic dodecapeptides to the Y2-receptor. None of the cyclic segments exhibits significant affinity to the Y1-receptor. Thus, these results support the hypothesis of a discontinuous binding site of neuropeptide Y at the Y1-receptor.Keywords
This publication has 43 references indexed in Scilit:
- Modified, cyclic dodecapeptide analog of neuropeptide Y is the smallest full agonist at the human Y2 receptorFEBS Letters, 1996
- Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide YNature, 1996
- Cloning and Functional Expression of a Human Y4 Subtype Receptor for Pancreatic Polypeptide, Neuropeptide Y, and Peptide YYJournal of Biological Chemistry, 1995
- Expression Cloning and Pharmacological Characterization of a Human Hippocampal Neuropeptide Y/Peptide YY Y2 Receptor SubtypePublished by Elsevier ,1995
- Cloning and Functional Expression of a cDNA Encoding a Human Type 2 Neuropeptide Y ReceptorJournal of Biological Chemistry, 1995
- A rational approach for the development of reduced‐size analogues of neuropeptide Y with high affinity to the Y1 receptorJournal of Peptide Science, 1995
- α‐Helical small molecular size analogues of neuropeptide Y: Structure‐activity relationshipsBiopolymers, 1991
- Structure/activity relationships of C‐terminal neuropeptide Y peptide segments and analogues composed of sequence 1–4 linked to 25–36European Journal of Biochemistry, 1990
- Highly potent and small neuropeptide Y agonist obtained by linking NPY 1–4 via spacer to α‐helical NPY 25–36FEBS Letters, 1989
- Conformational studies on the pancreatic polypeptide hormone familyEuropean Journal of Biochemistry, 1984